---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000044"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:38:35.983223+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akebia settles all patent disputes with FibroGen and Astellas in EU, UK, Japan

## Summary
- Settlement covers European (UK) Patent Nos. 2289531, 1463823, 2322155, 1633333, 2322153, 2298301 and Japanese Patent Nos. 4845728, 5474741, 5474872.
- Resolves FibroGen's opposition to Akebia's European Patent No. 3357911 before the European Patent Office.
- All ongoing litigation in UK courts and Japan Intellectual Property High Court to be terminated under agreement.
- No financial terms or other business impact disclosed in the filing.

## SEC filing metadata
- accession: 0001517022-23-000044
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000044/0001517022-23-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000044/akba-20231121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000044
- JSON: https://secwatch.observer/filing/0001517022-23-000044.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.